Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The cleanroom operates under stringent ISO Class 5 conditions, using ultrapure water and air systems
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Subscribe To Our Newsletter & Stay Updated
